Recurrent regions of LOH included the loci of RB1 (chromosome 13q14.2) and TP53 (chromosome 17p13.1) (Figure 6C), with 88% and 63% of mutational events co-occurring with LOH, respectively (Figure 2B), highlighting how the LOH background makes USARCs propitious to double-hits on tumor suppressors. Conversely, there were retained regions of heterozygosity on chromosomes 1, 2, 4, 5, 7, 9, 19, and 21 in >80% of samples (Figure 6C). Here, TP53 is linked to neoplasm.